This is a revised competitive renewal of NIH T32HL-07910 undid since 1999.
The aim i s to continue training the next generation of scientists in the clinically-relevant medical area of gene transfer for effective modulation of normal cell growth, and gene therapy. We request 4 pre- and 5 postdoctoral positions and 1 short term pre-doc slot for a minority student. Pre- and post-doctoral trainees will be trained 3-4 and 2-3 years, respectively. We assembled an outstanding group of 24 productive/interactive investigators from 8 departments of the medical school (Microbiology/Immunology, Biochemistry/Molecular Biology, Pharmacology/Toxicology, Medical/ Mol-cular Genetics, Medicine, Pediatrics, General Surgery and Urology) who have trained pre- and/or post-doctorals with multidisciplinary approaches using different cell types. Training emphasis is on hematopoietic stem (HSC) cells and blood cells, but includes studies with other cell types for gene modification to enhance collaboration/training experiences. The PI studies HSC, hematopoietic, and gene replacement, published >640 papers ,is on numerous editorial boards/NIH/other review/advisory committees, is cun'ent Pres-Elect of ASH, trained 66 pre/post docs. The Co-PI is recognized in the gene therapy and viral vector production area, has published >100 refereed papers in these areas, is Pres-Elect of ASGT, has trained >10 students/fellows. The PI/Co-PI are part of a long-term funded PPG on gene therapy along with 6 other preceptors on the program, and the program includes a nationally- recognized and funded clinical grade gene vector production facility. Our preceptors have extensive collaboration , co-publish with each other, have all labs within 5-10 minute walking distance and are dedicated to training students in gene transfer/therapy. Training entails one-on-one interactions, formal committee meetings, lab meetings, special seminar series, didactic courses, ethical training and scientific meeting presentations. An Internal and External Advisory Committee will monitor student/mentor progress. Our past students are employed in academia, and biotech and pharmaceutical companies. This training will enhance the future of gene transfer/therapy for basic understanding and treatment of disease.
|Sisti, Flavia; Wang, Soujuan; Brandt, Stephanie L et al. (2018) Nuclear PTEN enhances the maturation of a microRNA regulon to limit MyD88-dependent susceptibility to sepsis. Sci Signal 11:|
|Varberg, Kaela M; Winfree, Seth; Dunn, Kenneth W et al. (2018) Kinetic Analysis of Vasculogenesis Quantifies Dynamics of Vasculogenesis and Angiogenesis In Vitro. J Vis Exp :|
|Deng, Lisa; Richine, Briana M; Virts, Elizabeth L et al. (2018) Rapid development of myeloproliferative neoplasm in mice with Ptpn11 D61Y mutation and haploinsufficient for Dnmt3a. Oncotarget 9:6055-6061|
|Walline, Crystal C; Blum, Janice S; Linton, Tobyn et al. (2018) Early activation of peripheral monocytes with hallmarks of M1 and M2 monocytic cells in excessive alcohol drinkers: a pilot study. J Investig Med 66:1-4|
|Cai, Zhigang; Kotzin, Jonathan J; Ramdas, Baskar et al. (2018) Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis. Cell Stem Cell 23:833-849.e5|
|Patterson, Andrea M; Pelus, Louis M (2018) Spotlight on Glycolysis: A New Target for Cord Blood Expansion. Cell Stem Cell 22:792-793|
|Ren, Hong-Gang; Adom, Djamilatou; Paczesny, Sophie (2018) The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease. Expert Rev Clin Immunol 14:389-404|
|Varberg, Kaela M; Winfree, Seth; Chu, Chenghao et al. (2017) Kinetic analyses of vasculogenesis inform mechanistic studies. Am J Physiol Cell Physiol 312:C446-C458|
|Clinkenbeard, Erica L; Hanudel, Mark R; Stayrook, Keith R et al. (2017) Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica 102:e427-e430|
|Hum, Julia M; Clinkenbeard, Erica L; Ip, Colin et al. (2017) The metabolic bone disease associated with theHypmutation is independent of osteoblastic HIF1? expression. Bone Rep 6:38-43|
Showing the most recent 10 out of 114 publications